Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

BPH: later-stage trial registry

3 of 6 indexed BPH trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count

BPH: 6 US clinical trials tracked, 3 recruiting.

BPH is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Prostate Laser Center, P, running 1 of these trials.

Enrollment posture brief

Registry condition bph

OPEN 3 | RECR 50% | LATE 1 | EARLY 0 | RANK #2866 | SPON 1

Nearest open-share peer: Achalasia (50% recruiting · 8 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%BPH (this)50%
Open-enrollment share among volume-matched conditions near BPH

BPH lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for BPH on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. BPH is recruiting above its size-band peers.

    3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates BPH research.

    Prostate Laser Center, P accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most BPH trials plan to enrol fewer than 100 people.

    Median target enrolment is 80 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. BPH splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Named interventions

Most-linked intervention names on BPH records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Prostatic Artery Embolization Device
1 trials
MRI Guided Transrectal Periuretheral Transitional Zone Ablation Device
1 trials
Alfuzosin 10 mg Drug
1 trials
Group preoperative pelvic floor training Behavioral
1 trials
Furosemide Drug
1 trials
Mri-uds; Us-uds; Mcud Device
1 trials

US sites by state

Facility locations filed on BPH trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Virginia 1 trials
Texas 1 trials
Ohio 1 trials
North Carolina 1 trials
Illinois 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this BPH page

6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This BPH condition card totals 6 registered trials; most-linked intervention Prostatic Artery Embolization; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.